ELUTIA INC.

ELUT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $53.4M $-53.9M $-37.7M $-32.9M $-24.8M $-21.8M $-11.9M
Depreciation & Amortization $2.8M $3.5M $3.7M $3.7M $3.7M $3.9M $3.9M
Depreciation $100.0K $100.0K $100.0K $300.0K $500.0K $500.0K
Amortization $1.1M $1.1M $3.4M $3.4M $3.4M $3.4M $3.4M
Stock-Based Compensation $5.2M $7.9M $2.4M $3.6M $3.5M $779.0K $208.0K
Net Cash from Operating Activities $-44.8M $-22.7M $-21.8M $-21.4M $-15.4M $-13.6M $-7.2M
Investing Activities
Capital Expenditures $1.9M $654.0K $346.0K $540.0K $369.0K $640.0K $577.0K
Business Acquisitions
Net Cash from Investing Activities $78.6M $-474.0K $14.2M $-540.0K $-369.0K $-640.0K $-577.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-10.6M $17.1M $9.8M $8.5M $6.7M $51.2M $8.0M
Net Change in Cash
Free Cash Flow $-46.7M $-23.3M $-22.1M $-22.0M $-15.8M $-14.3M $-7.8M